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(adherent), $12,619 (partially adherent) and $8,675 (non-adher-
ent). The adherent class had a lower average cost than the non-
adherent class in all the cost categories but drug costs were
$1,939 higher (all p-values <0.05). CONCLUSION: Multiple
indicators of adherence to antipsychotic medication capture het-
erogeneity in non-adherence behaviors, which can be modeled
using latent classes, so deﬁne non-adherence casemix.
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OBJECTIVE: To determine the relationship between ziprasidone
starting dose and persistence among patients diagnosed with
schizophrenia. METHODS: Adult Medicaid recipients diag-
nosed with schizophrenia and having ziprasidone prescription
claims between July 1, 2001 and September 30, 2003 were cat-
egorized by starting dosage: low (20–60mg) n = 517; medium
(61mg–119mg) n = 339; and high (120–160mg) n = 341. Per-
sistence was measured using reﬁll patterns, allowing 15-day gaps
between expected reﬁll dates, and compared across starting doses
using Chi-Square tests. Multivariate logistic analysis explored
the simultaneous impact of age, gender, race, and year of treat-
ment initiation in addition to starting dose. RESULTS: Discon-
tinuation rates across the study period (maximum 30 months)
were greater for patients initiated with low (p = 0.001) and
medium dose (p = 0.02) than for high dose patients. Discontin-
uation rates were not statistically different for low and medium
doses. Discontinuation rates at 365, 180, and 90 days were
higher for low dose than high dose (p < 0.05) but not signiﬁ-
cantly different between low and medium or medium and high
doses. These results were similar in the multivariate models.
CONCLUSIONS: Schizophrenia patients started on high doses
of ziprasidone have greater persistence up to 21/2 years than those
who start on low doses.
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OBJECTIVES: The primary objective compared antipsychotic
non-adherence rates of outpatients with schizophrenia or
schizoaffective disorder as assessed by electronic monitoring vs.
prescriber ratings. Secondary objectives evaluated the relation-
ship between electronically-determined antipsychotic adherence
with (1) various baseline patient characteristics and (2) prospec-
tively assessed symptom severity, quality of life (QoL) and cog-
nition. METHODS: Adult outpatients with schizophrenia or
schizoaffective DSM-IV diagnosis, taking a single oral antipsy-
chotic, and who signed informed consent were eligible. Adher-
ence was measured via electronic-monitored medication vial
caps, prescriber report, patient self-report and research assistant
report, at baseline and monthly for up to six-months, as were
symptom severity (PANSS) and QoL (SQLS, LOF, PSP). Patients
were non-adherent if adherence was <70% for two or more
months during the six-month study. A single cognition assess-
ment (BACS) was performed. RESULTS: Sixty-one patients
(mean age 44.3, b9.1 years, 51% female, illness duration 21.2,
b 10.7 years) were included. Antipsychotic non-adherence detec-
tion was signiﬁcantly higher with electronic monitoring (57%)
vs. prescriber assessment (7%; p < 0.0001, N = 60) and vs.
patient self-assessment (5%; p < 0.0001), but was not different
from research assistant assessment (54%; p < 0.67). While the
total number of patients classiﬁed as adherent and non-adherent
by research assistants and electronic monitoring were similar,
disagreement in assignment occurred in 36% of cases. Poorer
mean adherence was associated with baseline characteristics of
less than high school education (p < 0.0001), non-Caucasian race
(p = 0.001), and more severe symptoms (p = 0.001). Lower mean
adherence rates were also associated with worse mean six-month
symptom (PANSS total; p < 0.002) and lower functioning on one
of three QoL scales (SQLS; p < 0.03) ratings. No relationship
was found between adherence and cognition. CONCLUSION:
In patients with schizophrenia and schizoaffective disorder, non-
adherence is signiﬁcantly underestimated/underreported by pre-
scribers and patients. Results suggest non-adherence with
antipsychotic medication therapy is associated with worse symp-
toms, poorer QoL, less than high school education and non-
Caucasian race.
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OBJECTIVES: To evaluate long-term clinical and economic out-
comes in patients participating in the ongoing Electronic Schiz-
ophrenia Treatment Adherence Registry in Germany, who were
initiated on long-acting injectable risperidone (LAIR). Baseline
and retrospective data will be presented. METHODS: Data are
collected via a secured web-based system for 12 months retro-
spectively and for 2 years prospectively. Data collected include
patient demographics, treatment and hospitalisation history,
reason for initiating new antipsychotic treatment, Clinical
Global Impression—Severity (CGI-S), Global Assessment of
Functioning (GAF) and adverse events. RESULTS: Complete
baseline and retrospective data are available for 744 patients.
Mean (±SD) age is 41.0 years (±12.2), 56% of patients are male,
and 97% have a diagnosis of schizophrenia or schizoaffective
disorder. The mean (±SD) duration of illness at the time of LAIR
initiation is 9.2 (±9.1) years. Eighty-six percent of patients had
a CGI-S score of moderate (30.5%), marked (35.5%) or severe
(20.3%). The mean (±SD) GAF score was 46 (±15). Seventy-two
percent of patients had at least one hospitalisation during the
year before LAIR initiation; 39% patients received oral atypi-
cals, 5% oral conventionals, 15% depot conventionals, and 31%
received different types of antipsychotics simultaneously or
sequentially in the year preceding LAIR initiation. For 10% of
patients, no retrospective medication information was indicated.
The most frequent reasons for LAIR initiation were lack of com-
pliance (37%), insufﬁcient response (27%), and unacceptable
tolerability (16%) with the previous medication(s). Fifty-three
percent of patients started on 25mg/14 days of long-acting
risperidone, 31% on 37.5mg/14 days and 16% on 50mg/14
days. CONCLUSIONS: Patients in this sample demonstrate dis-
tinct symptomatology and impairment in functioning. Despite a
considerable proportion of patients previously treated with novel
